Nothing Special   »   [go: up one dir, main page]

NO972816D0 - Farmasöytisk blanding omfattende mirtazapine og én eller flere selektive serotinin-gjenopptaks-inhibitorer - Google Patents

Farmasöytisk blanding omfattende mirtazapine og én eller flere selektive serotinin-gjenopptaks-inhibitorer

Info

Publication number
NO972816D0
NO972816D0 NO972816A NO972816A NO972816D0 NO 972816 D0 NO972816 D0 NO 972816D0 NO 972816 A NO972816 A NO 972816A NO 972816 A NO972816 A NO 972816A NO 972816 D0 NO972816 D0 NO 972816D0
Authority
NO
Norway
Prior art keywords
mirtazapine
pharmaceutical composition
reuptake inhibitors
selective
serotinin reuptake
Prior art date
Application number
NO972816A
Other languages
English (en)
Other versions
NO313177B1 (no
NO972816L (no
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO972816(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO972816D0 publication Critical patent/NO972816D0/no
Publication of NO972816L publication Critical patent/NO972816L/no
Publication of NO313177B1 publication Critical patent/NO313177B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19972816A 1996-06-19 1997-06-18 Farmasöytisk blanding omfattende mirtazapin og ±n eller flere selektive serotonin-gjenopptaks-inhibitorer, anvendelse derav ogpakning NO313177B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (3)

Publication Number Publication Date
NO972816D0 true NO972816D0 (no) 1997-06-18
NO972816L NO972816L (no) 1997-12-22
NO313177B1 NO313177B1 (no) 2002-08-26

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19972816A NO313177B1 (no) 1996-06-19 1997-06-18 Farmasöytisk blanding omfattende mirtazapin og ±n eller flere selektive serotonin-gjenopptaks-inhibitorer, anvendelse derav ogpakning

Country Status (25)

Country Link
US (1) US5977099A (no)
JP (2) JP4925074B2 (no)
KR (1) KR100481254B1 (no)
CN (1) CN1132581C (no)
AR (1) AR007609A1 (no)
AT (1) ATE213159T1 (no)
AU (1) AU727851B2 (no)
BR (1) BR9703624A (no)
CA (1) CA2208199C (no)
CZ (1) CZ290691B6 (no)
DE (1) DE69710390T2 (no)
DK (1) DK0813873T3 (no)
ES (1) ES2172744T3 (no)
HK (1) HK1006081A1 (no)
HU (1) HU225534B1 (no)
ID (1) ID17051A (no)
IL (1) IL121076A (no)
NO (1) NO313177B1 (no)
NZ (1) NZ328113A (no)
PL (1) PL188520B1 (no)
PT (1) PT813873E (no)
RU (1) RU2181287C2 (no)
SG (1) SG60073A1 (no)
TR (1) TR199700522A2 (no)
ZA (1) ZA975335B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
AU737590B2 (en) * 1997-11-14 2001-08-23 N.V. Organon Use of mirtazapine for treating sleep apneas
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
RU2268725C2 (ru) * 2000-01-19 2006-01-27 Акцо Нобель Н.В. Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
WO2002036113A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ES2296893T3 (es) * 2001-02-12 2008-05-01 N.V. Organon Uso de mirtazapina para el tratamiento de la depresion severa en un paciente humano y portador del gen de la apolipoproteina e4.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
WO2003079886A2 (en) * 2002-03-21 2003-10-02 Hinz Martin C Serotonin and catecholamine system segment optimization techonology
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
KR100858852B1 (ko) 2002-12-27 2008-09-17 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) * 2003-02-21 2005-11-08 C Hinz Martin Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
ES2639579T3 (es) 2003-04-29 2017-10-27 Orexigen Therapeutics, Inc. Composiciones para afectar la pérdida de peso que comprende un antagonista opioide y bupropión
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
CA2585317C (en) * 2004-11-19 2015-02-24 N.V. Organon Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060963A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
WO2010143628A1 (ja) 2009-06-09 2010-12-16 住友重機械工業株式会社 ハイブリッド式ショベル及びその制御方法
KR101414012B1 (ko) * 2009-11-13 2014-07-01 주식회사 녹십자 아릴피페라진-함유 퓨린 유도체 및 그의 용도
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
KR20240090733A (ko) 2012-06-06 2024-06-21 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DE69005992T2 (de) * 1989-12-06 1994-05-05 Akzo Nv Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen.
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物

Also Published As

Publication number Publication date
CN1132581C (zh) 2003-12-31
DE69710390D1 (de) 2002-03-21
NO313177B1 (no) 2002-08-26
JP4925074B2 (ja) 2012-04-25
AU727851B2 (en) 2001-01-04
PL188520B1 (pl) 2005-02-28
NZ328113A (en) 1999-09-29
ES2172744T3 (es) 2002-10-01
PT813873E (pt) 2002-06-28
RU2181287C2 (ru) 2002-04-20
CA2208199A1 (en) 1997-12-19
KR100481254B1 (ko) 2005-09-12
HK1006081A1 (en) 1999-02-12
BR9703624A (pt) 1998-09-01
PL320628A1 (en) 1997-12-22
HU9701068D0 (en) 1997-08-28
IL121076A (en) 2000-10-31
ATE213159T1 (de) 2002-02-15
NO972816L (no) 1997-12-22
CA2208199C (en) 2006-10-24
CZ187097A3 (cs) 1998-01-14
HUP9701068A3 (en) 2000-07-28
TR199700522A3 (tr) 1998-01-21
AU2612997A (en) 1998-01-08
ZA975335B (en) 1998-01-26
US5977099A (en) 1999-11-02
JP2009137970A (ja) 2009-06-25
CZ290691B6 (cs) 2002-09-11
SG60073A1 (en) 1999-02-22
DK0813873T3 (da) 2002-05-27
KR980000447A (ko) 1998-03-30
MX9704579A (es) 1998-07-31
TR199700522A2 (xx) 1998-01-21
HUP9701068A2 (hu) 1998-08-28
JPH1067663A (ja) 1998-03-10
AR007609A1 (es) 1999-11-10
ID17051A (id) 1997-12-04
DE69710390T2 (de) 2002-08-14
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
CN1173330A (zh) 1998-02-18

Similar Documents

Publication Publication Date Title
NO972816D0 (no) Farmasöytisk blanding omfattende mirtazapine og én eller flere selektive serotinin-gjenopptaks-inhibitorer
NO955034L (no) Nye substituerte 1H-imidazoler og farmasöytiske preparater inneholdende disse
IS2081B (is) Nýir þrombínhemlar, framleiðsla þeirra og notkun
BR9711218A (pt) Composi-Æo eletrodeposit vel m-todo para sua produ-Æo e substrato
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
DK1105123T3 (da) Farmaceutiske præparater indeholdende lipase-inhibitorer og chitosan
IS1738B (is) Búnaður til þess að sökkva og lyfta fiskeldiseiningu
NO981426D0 (no) Fremgangsmåte og anordning for primær-brönn-sementering
NO992297D0 (no) FremgangsmÕte og nye forbindelser
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
DK0623612T3 (da) Polymorf terazosin og farmaceutisk sammensætning
PT956294E (pt) Inibidores da trombina
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
DK0804078T3 (da) Sammensætning og anvendelse deraf
DE59813583D1 (de) Tablettentestgerät
ID17792A (id) Penghambat penghambat metaloproreinase matriks
NO955138D0 (no) Aktivert smektittleire, og fremstilling derav
DK0984960T3 (da) N-triazol-2-indolcarboxamider og deres anvendelse som CCK-A-agonister
DK1068238T3 (da) Integrinheterodimer og subunit deraf
DE59703450D1 (de) Tablettenprüfgerät
NO983802D0 (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmÕter
NO20003268D0 (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
PT948483E (pt) Inibidores da farnesil-transferase
NO983346L (no) Tamoxifen og analoger derav
DK1243590T3 (da) Nukleotid-analog sammensætning og syntesemetode